In what could open the door to a potential cure for multiple
myeloma, Swedish scientists have discovered that a single antibody — a
protein used by the immune system to fight infection and disease — could
be the key to treating the cancer of the blood, which now has no
effective long-term treatment.
Researchers at Lund University in Sweden tested thousands of
antibodies to identify one in particular — known as BI-505 — that they
said was shown to have “a powerful effect on the tumor cells in both
cell studies and animal experiments.” Preliminary tests of BI-505 on
seriously ill patients also found it to be safe, and another study of
its treatment effects on newly diagnosed individuals has just begun.
“We tested the antibody in various ways, including on tumor cells
from myeloma patients that have been transplanted into mice,” said Lund
researcher Markus Hansson. “The tests showed that the antibody is able
to destroy myeloma cells.”
Special: This Small Group of Doctors is Quietly Curing Cancer
Myeloma develops when cells in the bone marrow become cancerous,
disrupting blood formation and resulting in fatigue, weakened bones, and
life-threatening kidney failure. Several drugs are currently used to
treat multiple myeloma, but none eradicate the disease. There is no
cure. Fewer than half of all patients diagnosed with the condition live
longer than five years.
Drugs based on antibodies, which are a part of the immune system
and fight off foreign bodies, are a promising new line of medical
research and are now used to treat some inflammatory diseases and types
of cancer.
The new Lund study will involve 15 patients and is expected to be
completed this year. If the results are promising, Hansson and his
colleagues will test BI-505 in larger studies designed to uncover the
best way of using the new antibody — alone or in combination with other
drugs.
No comments:
Post a Comment